vantictumab vænˈtɪktʊmæb human monoclonal antibody designed treatment drug developed oncomed pharmaceuticals inc partnership oncomed awarded patent set expire april bayer terminated option license inhibits wnt signalling targeting frizzled receptors cancer phase trials completed pancreatic cancer nonsmall cell lung cancer breast cancer results reported phase clinical trial triplenegative breast pancreatic monoclonal article stub help wikipedia expanding ithttpsenwikipediaorgwikivantictumab